Barrett's esophagus: proton pump inhibitors and chemoprevention I.

Abstract

The following on proton pump inhibitors and chemoprevention in Barrett's esophagus includes commentaries on normalization of esophageal refluxate; the effects of 5-HT(4) agonists on EGF secretion and of lubripristone on chloride channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association Probability in the evaluation of potential response to treatment.

• Authors: George Triadafilopoulos, Antonio Taddei, Paolo Bechi, Giancarlo Freschi, Maria Novella Ringressi, Duccio Rossi Degli'Innocenti, Francesca Castiglione, Emmanuella Masini, Marek Majewski, Grzegorz Wallner, Jerzy Sarosiek, John F Dillon, Richard C McCallum, Katerina Dvorak, Aaron Goldman, Philip Woodland, Daniel Sifrim, Joel E Richter, Michael Vieth, Helmut Neumann, Cord Langner, Norihisa Ishimura, Yuji Amano, Valter Nilton Felix
• Journal: Annals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 1232 Pg. 93-113 (Sep 2011) ISSN: 1749-6632 [Electronic] United States
• PMID: 21950809 (Publication Type: Journal Article, Review)
• Copyright: © 2011 New York Academy of Sciences.

Chemical References

• Proton Pump Inhibitors

Topics

• Barrett Esophagus (drug therapy, pathology, prevention & control)
• Chemoprevention
• Humans
• Proton Pump Inhibitors (therapeutic use)